Grundlæggende statistik
| CIK | 1412558 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Evotec SE - ADR
SEC Filings (Chronological Order)
Denne side giver en komplet, kronologisk liste over SEC-arkiveringer, eksklusive ejerskabsregistreringer, som vi leverer andre steder.
| August 13, 2025 |
Exhibit 99.1 interim STATEMENT 6M 2025 HIGHLIGHTS 🞂 CHANGING REVENUE MIX ALIGNED WITH NEW STRATEGY FOR SUSTAINABLE PROFITABLE GROWTH 🞂 NAME OF REPORTING SEGMENT UPDATED TO BETTER REFLECT STRATEGIC FOCUS: DISCOVERY & PRECLINICAL DEVELOPMENT (D&PD, FORMER SHARED R&D), EFFECTIVE IMMEDIATELY; JUST – EVOTEC BIOLOGICS (JEB) UNCHANGED 🞂 CONTINUATION OF TRENDS SEEN SINCE START OF THE YEAR: D&PD BASE |
|
| August 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2025 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 (Address of principal executive |
|
| July 30, 2025 |
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014 Exhibit 99.1 Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014 Ad hoc: Evotec SE and Sandoz AG planning potential sale of Just – Evotec Biologics Toulouse site Hamburg, Germany – Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ: EVO) announces the signing of a non-binding agreement with Sand |
|
| July 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2025 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 (Address of principal executive of |
|
| July 30, 2025 |
Exhibit 99.2 Evotec and Sandoz evolve their strategic partnership and agree on potential sale of Just – Evotec Biologics Toulouse site · Evotec SE and Sandoz AG signed a non-binding term sheet on a planned sale of Just – Evotec Biologics EU in Toulouse to Sandoz · Under the proposed deal Evotec would transfer biosimilar manufacturing capabilities to enable Sandoz to produce biosimilar medicines us |
|
| July 21, 2025 |
Exhibit 99.2 Evotec adjusts revenue guidance and confirms profit guidance anticipating a more profitable revenue mix • Successful execution of new strategy for sustainable and profitable growth leading to changing revenue mix with strong demand for Evotec’s differentiated platforms • High-margin technology license revenues expected to have a stronger impact than anticipated • Significant cost opti |
|
| July 21, 2025 |
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014 Exhibit 99.1 Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014 Ad hoc: Evotec SE adjusts revenue guidance while confirming profit guidance Hamburg, Germany – Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ: EVO) announces that it has updated its revenue guidance for the fiscal year 2025. Gu |
|
| July 21, 2025 |
6-K 1 tm2521309d16k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2025 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 ( |
|
| June 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2025 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 (Address of principal executive of |
|
| June 3, 2025 |
Exhibit 99.1 Evotec SE: Results of the Annual General Meeting 2025 • All agenda items adopted • Under the topic “Pioneering Drug Discovery” CEO Dr Christian Wojczewski presented Evotec’s current situation and strategic outlook • 46.45% of the registered share capital represented Hamburg, Germany, 03 June 2025: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) |
|
| May 6, 2025 |
Exhibit 99.1 For further information, please contact: Volker Braun, EVP Head of Global Investor Relations & ESG, [email protected], M. +49.(0)40 228 999 338, www.evotec.com interim STATEMENT 3M 2025 HIGHLIGHTS 4 START TO THE YEAR AS ANTICIPATED: SHARED R&D WITH SIMILAR TREND AS 2024; JUST – EVOTEC BIOLOGICS WITH CONTINUING GROWTH MOMENTUM 4 SIGNIFICANT PROGRESS IN STRATEGIC PROTEIN DEGRADATI |
|
| May 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2025 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 (Address of principal executive off |
|
| April 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2025 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 (Address of principal executive o |
|
| April 17, 2025 |
Articles of Association of Evotec SE General Provisions § 1 Company and Registered Office Exhibit 1.1 Non-binding convenience translation Articles of Association of Evotec SE I. General Provisions § 1 Company and Registered Office (1)The name of the Company shall be: Evotec SE. (2)The registered office of the Company shall be in Hamburg. § 2 Object of the Company (1) The object of the Company shall be research activities in the field of biologically functional synthetic, semi-synthetic |
|
| April 17, 2025 |
Exhibit 11.1 CONFIDENTIAL - This document is the confidential property of the Evotec group of companies and is for the sole use of members of Evotec staff. Page 1 of 9 Evotec Group Group Policy on Insider Information Document: Revision version No. 2 Effective Date: 19 April 2024 Author: Legal & Compliance Department Reviewed by: Management Board and Supervisory Board Approved by: Management Board |
|
| April 17, 2025 |
Evotec SE unveils new strategy and provides 2025 guidance bolstered by strong Q4 2024 results Exhibit 99.1 Evotec SE unveils new strategy and provides 2025 guidance bolstered by strong Q4 2024 results · Evotec sharpens focus on pioneering drug discovery and charts clear path toward sustainable profitable growth · Strategy builds on technology and science leadership, focusing on high-growth, high-value segments, simplifying the business model and fostering operational excellence · Strong Q4 |
|
| April 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 20-F Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF |
|
| April 17, 2025 |
Exhibit 12.1 CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO EXCHANGE ACT RULE 13A-14(A) OR 15D-14(A) AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Dr. Christian Wojczewski, certify that: 1. I have reviewed this annual report on Form 20-F of Evotec SE; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to st |
|
| April 17, 2025 |
Exhibit 12.2 CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER PURSUANT TO EXCHANGE ACT RULE 13A-14(A) OR 15D-14(A) AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Paul Hitchin, certify that: 1. I have reviewed this annual report on Form 20-F of Evotec SE; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a materi |
|
| April 17, 2025 |
European Union / Federal Republic of Germany Exhibit 2.3 DESCRIPTION OF SECURITIES The following description sets forth certain material terms and provisions of ordinary shares and American Depositary Shares representing ordinary shares of Evotec SE (“us,” “our,” “we” or the “Company”) that are registered under Section 12 of the U.S. Securities Exchange Act of 1934, as amended. This description also summarizes certain provisions of our artic |
|
| April 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2025 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 (Address of principal executive o |
|
| April 17, 2025 |
Exhibit 13.2 CERTIFICATION BY THE PRINCIPAL FINANCIAL OFFICER PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Evotec SE (the “Company”) on Form 20-F for the fiscal year ended December 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Paul Hitchin, Chief Financial Officer of the Company, certify, pur |
|
| April 17, 2025 |
Evotec announces change in Management Board Exhibit 99.1 Evotec announces change in Management Board • Laetitia Rouxel steps down as Chief Financial Officer effective 28 February 2025 • Paul Hitchin appointed to succeed as Chief Financial Officer effective 1 March 2025 Hamburg, Germany, 26 February 2025: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced that its Chief Financial Officer, |
|
| April 17, 2025 |
Exhibit 4.9 Promissory Notes (Schuldscheindarlehen) The five promissory note loan agreements (collectively, the “Promissory Notes”) each govern an unsecured promissory note loan among Evotec SE, as borrower (the “Borrower”), Deutsche Bank AG and Landesbank Baden-Württemberg (“LBBW,” and, together with the Borrower and Deutsche Bank AG, the “Parties”), as arrangers and LBBW as the original lender. |
|
| April 17, 2025 |
Exhibit 13.1 CERTIFICATION BY THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Evotec SE (the “Company”) on Form 20-F for the fiscal year ended December 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Dr. Christian Wojczewski, Chief Executive Officer of the Company, |
|
| April 17, 2025 |
Consent of Independent Registered Public Accounting Firm Exhibit 15.1 Consent of Independent Registered Public Accounting Firm Evotec SE Hamburg, Germany We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (No. 333-260920 and No. 333-272285) of Evotec SE (the “Company”) of our reports dated April 14, 2025, relating to the consolidated financial statements, and the effectiveness of Evotec SE’s internal control o |
|
| November 29, 2024 |
Evotec announces change in Management Board EXHIBIT 99.1 Evotec announces change in Management Board · Dr Craig Johnstone steps down as Chief Operating Officer effective 31 December 2024 · Distribution of responsibilities internally Hamburg, Germany, 29 November 2024: Evotec SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced that its Chief Operating Officer, Dr Craig Johnstone, will step down an |
|
| November 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2024 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 (Address of principal executiv |
|
| November 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2024 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 (Address of principal executiv |
|
| November 22, 2024 |
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014 Exhibit 99.1 Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014 Ad hoc: Comment on withdrawn non-binding offer Hamburg, Germany – Evotec SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ: EVO) Evotec SE has taken notice of the statement made by Halozyme Therapeutics Inc. on 22 November, stating that |
|
| November 15, 2024 |
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014 EXHIBIT 99.1 Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014 Ad hoc: Comment on media report Hamburg, Germany – Evotec SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ: EVO) With respect to a media report, Evotec SE (“Company”) declares that it has received, without prior contact, a non-binding e |
|
| November 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2024 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 (Address of principal executiv |
|
| November 8, 2024 |
EX-10.1 2 d872020dex101.htm EX-10.1 Exhibit 10.1 JOINT FILING AGREEMENT In accordance with the requirements of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and subject to the limitations set forth therein, the parties set forth below agree to jointly file the Schedule 13D to which this joint filing agreement is attached, and any subsequent amendments thereto, and have duty |
|
| November 8, 2024 |
EX-10.2 3 d872020dex102.htm EX-10.2 Exhibit 10.2 UBS AG, London Branch 5 Broadgate London EC2M 2QS Triton V LuxCo 113 SARL 2 rue Edward Steichen Luxembourg City 2540 Luxembourg Date: 27 October 2024 Equity Swap Transaction Dear Sirs The purpose of this letter agreement (this “Confirmation”) is to confirm the terms and conditions of the Equity Swap Transaction entered into between UBS AG, London Br |
|
| November 8, 2024 |
SC 13D 1 d872020dsc13d.htm SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Evotec SE (Name of Issuer) Ordinary Shares, no par value per share (Title of Class of Securities) 30050E105* (CUSIP Number) Pierre-Alexandre Lechantre Triton GP HoldCo SARL 2, rue Edward Steichen L-2540 Luxembourg, Grand |
|
| November 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 (Address of principal executive |
|
| November 6, 2024 |
Exhibit 99.2 Evotec Announces Sale of API Manufacturing Facility to Monacum Partners · Evotec divests chemical API-focused CDMO operation in Halle/Westphalia (Evotec DS) to Monacum Partners · Transaction aligns with Evotec’s strategic optimization efforts, concentrating resources on key growth drivers · New ownership committed to maintaining and growing the business Hamburg, 05 November 2024: Evot |
|
| November 6, 2024 |
Exhibit 99.1 For further information, please contact: Volker Braun, EVP Head of Global Investor Relations & ESG,[email protected], Phone +49 (0)40 228 999 338, Mobil +49.(0)40 228 999 338, www.evotec.com interim STATEMENT 9M 2024 HIGHLIGHTS 4 SUCCESSFUL EXTENSIONS AND EXPANSIONS OF STRATEGIC COLLABORATIONS WITH SANDOZ AND BMS 4 NEW PARTNERSHIP WITH NOVO NORDISK IN CELL THERAPY 4 GOOD ORDER T |
|
| August 14, 2024 |
Exhibit 13.2 Certification by the Principal Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of Evotec SE (the “Company”) on Form 20-F for the fiscal year ended December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Laetitia Rouxel, Chief Financial Officer of the Company, certify, |
|
| August 14, 2024 |
EVOTEC SE U.S. RESTRICTED SHARE UNIT PLAN Exhibit 4.15 EVOTEC US RSU PLAN TERMS 2023 EVOTEC SE U.S. RESTRICTED SHARE UNIT PLAN 1. Introduction and Purpose. This U.S. Restricted Share Unit Plan (this “Plan”) was adopted by the Management Board by resolution dated 14 February 2023. Terms capitalized but not defined shall have the definitions set forth in Section 2. The purpose of this Plan is to set forth principles and rules, which govern |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2024 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 (Address of principal executive |
|
| August 14, 2024 |
EVOTEC SE U.S. RESTRICTED SHARE UNIT PLAN AWARD AGREEMENT Exhibit 4.16 EVOTEC US RSU PLAN AWARD AGREEMENT EVOTEC SE U.S. RESTRICTED SHARE UNIT PLAN AWARD AGREEMENT This U.S. Restricted Share Unit Award Agreement (this “Agreement”) is entered into, effective as of 15 June 2023 (the “Grant Date”), by and between Evotec (the “Company”) and you (the “Participant”) pursuant and subject to the Evotec SE U.S. Restricted Share Unit Plan, as it may be amended fro |
|
| August 14, 2024 |
Exhibit 4.14 Contract number (FI No): 93512 Serapis No: 2021-0233 PROJECT JUSTICE Finance Contract originally dated 29 December 2022 between the European Investment Bank and Evotec SE as amended and restated on 10 February 2023 EIB Internal Classification Corporate Use Execution version originally dated 29 December 2022, as amended and restated on 10 February 2023 2 WHEREAS: ...................... |
|
| August 14, 2024 |
Exhibit 99.1 INTERIM STATEMENT 6M 2024 For further information, please contact: Volker Braun, EVP Head of Global Investor Relations & ESG, [email protected], M. +49.(0)151.1940 5058, www.evotec.com HIGHLIGHTS } SECOND QUARTER INFLUENCED BY VOLATILITY IN SHARED R&D PORTFOLIO AND CAPACITY RAMP-UP OF J.POD TOULOUSE, FRANCE } IMPROVED ORDER INTAKE IN DISCOVERY NOT FULLY TRANSLATING INTO REVENUES |
|
| August 14, 2024 |
European Union / Federal Republic of Exhibit 2.3 DESCRIPTION OF SECURITIES The following description sets forth certain material terms and provisions of ordinary shares and American Depositary Shares representing ordinary shares of Evotec SE (“us,” “our,” “we” or the “Company”) that are registered under Section 12 of the U.S. Securities Exchange Act of 1934, as amended. This description also summarizes certain provisions of our artic |
|
| August 14, 2024 |
Exhibit 2.4 WKN: 566480 ISIN: DE0005664809 Reference number: [·] [·] no-par stock Evotec SE Hamburg Global certificate for [·] bearer common stocks in the form of no-par stock Stock numbers: [·] to [·] The bearer of this global certificate is a shareholder of Evotec SE, Hamburg, in accordance with its Articles of Association and holds [·] no-par stocks. The number of stocks issued and certificated |
|
| August 14, 2024 |
Exhibit 4.9 Promissory Notes (Schuldscheindarlehen) The five promissory note loan agreements (collectively, the “Promissory Notes”) each govern an unsecured promissory note loan among Evotec SE, as borrower (the “Borrower”), Deutsche Bank AG and Landesbank Baden-Württemberg (“LBBW,” and, together with the Borrower and Deutsche Bank AG, the “Parties”), as arrangers and LBBW as the original lender. |
|
| August 14, 2024 |
Exhibit 1.1 Non-binding convenience translation A r t i c l e s o f A s s o c i a t i o n of Evotec SE I. General Provisions § 1 Company and Registered Office (1) The name of the Company shall be: Evotec SE. (2)The registered office of the Company shall be in Hamburg. § 2 Object of the Company (1) The object of the Company shall be research activities in the field of biologically functional synthe |
|
| August 14, 2024 |
Exhibit 13.1 Certification by the Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of Evotec SE (the “Company”) on Form 20-F for the fiscal year ended December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Dr. Christian Wojczewski, Chief Executive Officer of the Company, |
|
| August 14, 2024 |
Exhibit 12.2 CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER PURSUANT TO EXCHANGE ACT RULE 13A-14(A) OR 15D-14(A) AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Laetitia Rouxel, certify that: 1. I have reviewed this annual report on Form 20-F of Evotec SE; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a mat |
|
| August 14, 2024 |
Exhibit 4.17 EXECUTION VERSION 30 July 2024 EVOTEC SE (as the Company) EVOTEC SE (as Original Borrower and as Original Guarantor) COMMERZBANK AKTIENGESELLSCHAFT GOLDMAN SACHS LENDING PARTNERS LLC HSBC CONTINENTAL EUROPE S.A., GERMANY MORGAN STANLEY BANK AG UNICREDIT BANK GMBH (as Coordinating Bookrunners and Mandated Lead Arrangers) BNP PARIBAS S.A. NIEDERLASSUNG DEUTSCHLAND LANDESBANK BADEN-WÜRTT |
|
| August 14, 2024 |
Consent of Independent Registered Public Accounting Firm Exhibit 15.1 Consent of Independent Registered Public Accounting Firm Evotec SE Hamburg, Germany We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (No. 333-260920 and No. 333-272285) of Evotec SE of our reports dated August 12, 2024, relating to the consolidated financial statements, and the effectiveness of Evotec SE’s internal control over financial r |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 20-F Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF |
|
| August 14, 2024 |
Exhibit 12.1 CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO EXCHANGE ACT RULE 13A-14(A) OR 15D-14(A) AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Dr. Christian Wojczewski, certify that: 1. I have reviewed this annual report on Form 20-F of Evotec SE; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to st |
|
| August 14, 2024 |
EVOTEC – Compensation Clawback Policy Exhibit 10.1 Evotec Group Evotec Compensation Clawback Policy Evotec Compensation Clawback Policy Document: Version No.2 Table of Contents Effective Date: 1. Purpose 1 December 1, 2023 2. Scope 1 3. Key Definitions 1 4. Requirements 2 Author: 4.1 Recovery Triggered by Accounting Restatement 3 Global Legal & Compliance 4.2 Recovery Amount 3 4.3 No Recovery Required for De Minimis Amounts or Impract |
|
| August 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2024 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 (Address of principal executive |
|
| August 6, 2024 |
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014 Exhibit 99.1 Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014 Ad hoc: Evotec SE provides guidance update Hamburg, Germany, – Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ: EVO) announces that it has refined its guidance for the fiscal year 2024. The Company expects Group revenues in the |
|
| August 6, 2024 |
EVOTEC PROVIDES GUIDANCE UPDATE Exhibit 99.2 EVOTEC PROVIDES GUIDANCE UPDATE • Navigating through a challenging H1 2024: Unsatisfying revenue dynamics in Shared R&D; Just – Evotec Biologics with mid double-digit revenue growth versus strong comparable basis • Adjusted EBITDA impacted by high fixed cost base in Shared R&D and ramp-up costs for J.POD Toulouse, France • Further strengthened sales order book in Discovery is basis fo |
|
| June 10, 2024 |
EXHIBIT 99.2 |
|
| June 10, 2024 |
Results of the Annual General Meeting 2024 EXHIBIT 99.1 Results of the Annual General Meeting 2024 · Most agenda items adopted with great majority · Annual General Meeting 2024 elects Dr Duncan McHale and Wesley Wheeler to the Supervisory Board, replacing Dr Elaine Sullivan and Dr Mario Polywka Hamburg, Germany, 10 June 2024: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced that its sh |
|
| June 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF JUNE 2024 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 (Address of principal executive off |
|
| May 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2024 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 (Address of principal executive off |
|
| May 22, 2024 |
For further information, please contact Exhibit 99.1 For further information, please contact: Volker Braun, EVP Head of Global Investor Relations & ESG, [email protected], M. +49.(0)40 228 999 338, www.evotec.com interim STATEMENT 3M 2024 HIGHLIGHTS 4 CHALLENGING Q1 WITH SOFTNESS MAINLY IN TRANSACTIONAL/DEVELOPMENT SHARED R&D BUSINESS AGAINST A STRONG COMPARABLE QUARTER 4 STRONG START WITH JUST – EVOTEC BIOLOGICS IN Q1 2024 4 POSI |
|
| April 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 SEC FILE NUMBER 001-34041 CUSIP NUMBER 30050E105 NOTIFICATION OF LATE FILING (Check One) ¨ Form 10-K x Form 20-F ¨ Form 11-K ¨ Form 10-Q ¨ Form 10-D ¨ Form N-CEN ¨ Form N-CSR For Period Ended: December 31, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Tran |
|
| April 24, 2024 |
EXHIBIT 99.2 |
|
| April 24, 2024 |
EXHIBIT 99.3 |
|
| April 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF APRIL 2024 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 (Address of principal executive of |
|
| April 24, 2024 |
EXHIBIT 99.1 |
|
| April 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF April 2024 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 (Address of principal executive of |
|
| April 23, 2024 |
Evotec SE appoints Dr Christian Wojczewski as Chief Executive Officer EXHIBIT 99.1 Evotec SE appoints Dr Christian Wojczewski as Chief Executive Officer 23-Apr-2024 / 20:38 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. Hamburg, Germany – Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/Tec |
|
| April 23, 2024 |
EXHIBIT 99.2 |
|
| April 8, 2024 |
Exhibit 99.1 Notification of Major Holdings Page 1 | 4 Hamburg 22419 Essener Bogen 7 529900F9KI6OYITO9B12 Evotec SE X Notification of Major Holdings or Correction of a notification of Major Holdings dated 1. Details of issuer (name, address) Name Legal Entity Identifier (LEI) Street, Street number Postal code City 2. Reason for notification (multiple reasons possible) Acquisition/disposal of share |
|
| April 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF April 2024 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 (Address of principal executive of |
|
| February 14, 2024 |
EVTCY / Evotec SE - ADR / Novo Holdings A/S - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Evotec SE (Name of Issuer) Ordinary Shares, no par value per share (Title of Class of Securities) 30050E105 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| January 3, 2024 |
EXHIBIT 99.2 |
|
| January 3, 2024 |
Evotec announces CEO transition EXHIBIT 99.1 Evotec announces CEO transition Hamburg, Germany, – Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ: EVO) announces that CEO Dr Werner Lanthaler has informed the company, that he has decided to step down as CEO and will not continue to serve until the end of his current term, for personal reasons. The Supervisory Board h |
|
| January 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF JANUARY 2024 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 (Address of principal executive |
|
| November 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF NOVEMBER 2023 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 (Address of principal executive |
|
| November 8, 2023 |
Exhibit 99.2 Evotec SE reports results for the first nine months 2023 and provides corporate update 4 CONTINUATION OF STRONG GROWTH IN DEMANDING MARKETS 4 PARADIGM-SHIFTING OFFERINGS ARE STRONGEST GROWTH DRIVERS 4 PIPELINE PROGRESS, e.g. WITH ADVANCED ASSET IN NEURODEGENERATION 4 ALL ELEMENTS OF GUIDANCE CONFIRMED Hamburg, Germany, 08 November 2023: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/T |
|
| November 8, 2023 |
Exhibit 99.1 For further information, please contact: Volker Braun, SVP Head of Global Investor Relations & ESG, [email protected], M. +49(0)151.1940 5058, www.evotec.com interim STATEMENT 9M 2023 HIGHLIGHTS 4 CONTINUATION OF STRONG GROWTH IN DEMANDING MARKETS 4 PARADIGM-SHIFTING OFFERINGS ARE STRONGEST GROWTH DRIVERS 4 PIPELINE PROGRESS; E.G. WITH ADVANCED ASSET IN NEURODEGENERATION 4 ALL E |
|
| August 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2023 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 (Address of principal executive |
|
| August 29, 2023 |
EVOTEC SE U.S. RESTRICTED SHARE UNIT PLAN AWARD AGREEMENT Exhibit 99.3 EVOTEC US RSU PLAN AWARD AGREEMENT EVOTEC SE U.S. RESTRICTED SHARE UNIT PLAN AWARD AGREEMENT This U.S. Restricted Share Unit Award Agreement (this “Agreement”) is entered into, effective as of 15 June 2023 (the “Grant Date”), by and between Evotec (the “Company”) and you (the “Participant”) pursuant and subject to the Evotec SE U.S. Restricted Share Unit Plan, as it may be amended fro |
|
| August 29, 2023 |
Exhibit 99.1 For further information, please contact: Volker Braun, SVP Head of Global Investor Relations & ESG, [email protected], M. +49.(0)151.1940 5058, www.evotec.com HALF-YEAR REPORT 2023 I. MANAGEMENT REPORT 4 NEW AND EXTENDED ALLIANCES underline PIPELINE POTENTIAL 4 NEW GUIDANCE For full-year 2023 confIRMED HIGHLIGHTS Q2 CYBER-incident IMPACTING STRONG organic REVENUE GROWTH 4 Group |
|
| August 29, 2023 |
EVOTEC SE U.S. RESTRICTED SHARE UNIT PLAN Exhibit 99.2 EVOTEC US RSU PLAN TERMS 2023 EVOTEC SE U.S. RESTRICTED SHARE UNIT PLAN 1. Introduction and Purpose. This U.S. Restricted Share Unit Plan (this “Plan”) was adopted by the Management Board by resolution dated 14 February 2023. Terms capitalized but not defined shall have the definitions set forth in Section 2. The purpose of this Plan is to set forth principles and rules, which govern |
|
| July 27, 2023 |
EXHIBIT 99.2 |
|
| July 27, 2023 |
Evotec provides update on financial impact of cyber-attack EXHIBIT 99.1 Evotec provides update on financial impact of cyber-attack Hamburg, Germany, – Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ: EVO) announces that it is adjusting its guidance for the fiscal year 2023. Due to the impact of the cyber-attack, the company now expects Group revenues in the range of € 750 – 790 m (previously |
|
| July 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF JULY 2023 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 (Address of principal executive off |
|
| June 21, 2023 |
Exhibit 99.1 Notification of Major Holdings Page 1 12 | Hamburg 22419 Essener Bogen 7 529900F9KI6OYITO9B12 Evotec SE X Notification of Major Holdings or Correction of a notification of Major Holdings dated 1. Details of issuer (name, address) Name Legal Entity Identifier (LEI) Street, Street number Postal code City 2. Reason for notification (multiple reasons possible) X Acquisition/disposal of sh |
|
| June 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF JUNE 2023 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 (Address of principal executive off |
|
| June 20, 2023 |
EXHIBIT 99.2 |
|
| June 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF JUNE 2023 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 (Address of principal executive off |
|
| June 20, 2023 |
EXHIBIT 99.1 |
|
| May 30, 2023 |
Exhibit 107.1 Calculation of Filing Fee Table Form S-8 (Form Type) Evotec SE (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title(1) Fee Calculation Rule Amount Registered(2) Proposed Maximum Offering Price Per Unit(3) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Ordinary shares, no par value p |
|
| May 30, 2023 |
As filed with the Securities and Exchange Commission on May 30, 2023 As filed with the Securities and Exchange Commission on May 30, 2023 Registration No. |
|
| May 30, 2023 |
Exhibit 4.2 Execution Version TABLE OF CONTENTS Page PARTIES 1 RECITALS 1 Section 1. Certain Definitions (a) ADR Register 1 (b) ADRs; Direct Registration ADRs 1 (c) ADS 1 (d) Beneficial Owner 2 (e) CSB 2 (f) Custodian 2 (g) Deliver, execute, issue et al. 2 (h) Delivery Order 2 (i) Deposited Securities 2 (j) Direct Registration System 3 (k) Holder 3 (l) Securities Act of 1933 3 (m) Securities Excha |
|
| May 30, 2023 |
EVOTEC SE U.S. RESTRICTED SHARE UNIT PLAN Exhibit 10.1 EVOTEC US RSU PLAN TERMS 2023 EVOTEC SE U.S. RESTRICTED SHARE UNIT PLAN 1. Introduction and Purpose. This U.S. Restricted Share Unit Plan (this “Plan”) was adopted by the Management Board by resolution dated 14 February 2023. Terms capitalized but not defined shall have the definitions set forth in Section 2. The purpose of this Plan is to set forth principles and rules, which govern |
|
| May 30, 2023 |
EVOTEC SE U.S. RESTRICTED SHARE UNIT PLAN AWARD AGREEMENT Exhibit 10.2 EVOTEC US RSU PLAN AWARD AGREEMENT EVOTEC SE U.S. RESTRICTED SHARE UNIT PLAN AWARD AGREEMENT This U.S. Restricted Share Unit Award Agreement (this “Agreement”) is entered into, effective as of [ ] (the “Grant Date”), by and between Evotec (the “Company”) and you (the “Participant”) pursuant and subject to the Evotec SE U.S. Restricted Share Unit Plan, as it may be amended from time to |
|
| May 15, 2023 |
EXHIBIT 99.1 |
|
| May 15, 2023 |
6-K 1 evo6k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF MAY 2023 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 (Address of |
|
| May 12, 2023 |
Exhibit 12.2 CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER PURSUANT TO EXCHANGE ACT RULE 13A-14(A) OR 15D-14(A) AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I. Laetitia Rouxel, certify that: 1. I have reviewed this annual report on Form 20-F of Evotec SE: 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a mat |
|
| May 12, 2023 |
Exhibit 4.9 Promissory Notes (Schuldscheindarlehen) The five promissory note loan agreements (collectively, the “Promissory Notes”) each govern an unsecured promissory note loan among Evotec SE, as borrower (the “Borrower”), Deutsche Bank AG and Landesbank Baden-Württemberg (“LBBW,” and, together with the Borrower and Deutsche Bank AG, the “Parties”), as arrangers and LBBW as the original lender. |
|
| May 12, 2023 |
Exhibit 2.4 WKN: 566480 ISIN: DE0005664809 Reference number: [●] [●] no-par stock Evotec SE Hamburg Global certificate for [●] bearer common stocks in the form of no-par stock Stock numbers: [●] to [●] The bearer of this global certificate is a shareholder of Evotec SE, Hamburg, in accordance with its Articles of Association and holds [●] no-par stocks. The number of stocks issued and certificated |
|
| May 12, 2023 |
Exhibit 13.2 Certification by the Principal Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of Eyotec SE (the “Company”) on Form 20-F for the fiscal year ended December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Lactitia Rouxel, Chief Financial Officer of the Company, certify, |
|
| May 12, 2023 |
European Union / Federal Republic of Germany Exhibit 2.3 DESCRIPTION OF SECURITIES The following description sets forth certain material terms and provisions of ordinary shares and American Depositary Shares representing ordinary shares of Evotec SE (“us,” “our,” “we” or the “Company”) that are registered under Section 12 of the U.S. Securities Exchange Act of 1934, as amended. This description also summarizes certain provisions of our artic |
|
| May 12, 2023 |
Exhibit 4.14 Contract number (FI No): 93512 Serapis No: 2021-0233 PROJECT JUSTICE Finance Contract originally dated 29 December 2022 between the European Investment Bank and Evotec SE as amended and restated on 10 February 2023 EIB Internal Classification Corporate Use &(57$,1,'(17,),(',1)250$7,21+$6%((1(;&/8'(')5207+((;+,%,7%(&$86(,7,6 %27+ L 1270$7(5,$/$1' LL :28/'/,.(/<&$86(&203(7,7,9(+$50727+ |
|
| May 12, 2023 |
Exhibit 13.1 Certification by the Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of Evotec SE (the “Company”) on Form 20-F for the fiscal year ended December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Dr. Werner Lanthaler, Chief Executive Officer of the Company, cert |
|
| May 12, 2023 |
Exhibit 99.1 Notification of Major Holdings Page 1 | 11 Hamburg 22419 Essener Bogen 7 529900F9KI6OYITO9B12 Evotec SE X Notification of Major Holdings or Correction of a notification of Major Holdings dated 1. Details of issuer (name, address) Name Legal Entity Identifier (LEI) Street, Street number Postal code City 2. Reason for notification (multiple reasons possible) X Acquisition/disposal of sh |
|
| May 12, 2023 |
Exhibit 12.1 CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO EXCHANGE ACT RULE 13A-14(A) OR 15D-14(A) AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Dr. Werner Lanthaler, certify that: 1. I have reviewed this annual report on Form 20-F of Evotec SE; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state |
|
| May 12, 2023 |
Consent of Independent Registered Public Accounting Firm Exhibit 15.1 Consent of Independent Registered Public Accounting Firm Evotec SE Hamburg, Germany We hereby consent to the incorporation by reference in the Registration Statement on Form S-8 (No. 333-260920) of Evotec SE of our report dated May 10, 2023 relating to the consolidated financial statements and the effectiveness of Evotec SE’s internal control over financial reporting, which appears in |
|
| May 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 20-F Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF |
|
| May 12, 2023 |
Consent of Independent Registered Public Accounting Firm Exhibit 15.2 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the Registration Statement (Form S-8 No. 333-260920) pertaining to the Employees’ Restricted Share Plan 2020 and Share Performance Plan 2017 of Evotec SE of our report dated July 9, 2021 (except for Note 3, to which the date is August 19, 2021), with respect to the consolidated fin |
|
| May 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF MAY 2023 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 (Address of principal executive offi |
|
| May 12, 2023 |
Exhibit 1.1 Non-binding convenience translation A r t i c l e s o f A s s o c i a t i o n of Evotec SE I. General Provisions § 1 Company and Registered Office (1)The name of the Company shall be: Evotec SE. (2)The registered office of the Company shall be in Hamburg. § 2 Object of the Company (1) The object of the Company shall be research activities in the field of biologically functional synthet |
|
| May 9, 2023 |
Just – Evotec Biologics enters strategic biosimilars partnership with Sandoz EXHIBIT 99.1 Just – Evotec Biologics enters strategic biosimilars partnership with Sandoz Hamburg, Germany, – Evotec SE (Frankfurt Stock Exchange: EVT, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ: EVO) announces that Evotec’s Seattle-based subsidiary, Just – Evotec Biologics, Inc., has entered a multi-year, long-term tech partnership with Sandoz for the immediate development and subs |
|
| May 9, 2023 |
EXHIBIT 99.2 |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF MAY 2023 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 (Address of principal executive offi |
|
| May 2, 2023 |
NT 20-F 1 tm2311375d2nt20f.htm NT 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 001-34041 CUSIP NUMBER 30050E105 (Check one): ¨ Form 10-K x Form 20-F ¨ Form 11-K ¨ Form 10-Q ¨ Form 10-D ¨ Form N-CEN ¨ Form N-CSR For Period Ended: December 31, 2022 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F |
|
| April 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF APRIL 2023 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 (Address of principal executive of |
|
| April 7, 2023 |
EX-99.1 2 evoex991.htm CYBER ATTACK ON EVOTEC EXHIBIT 99.1 Cyber Attack on Evotec 07-Apr-2023 / 15:10 CET/CEST The issuer is solely responsible for the content of this announcement. Hamburg, Germany, – Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE 000 566480 9, WKN 566480; NASDAQ: EVO) announces that on 06 April, 2023 a cyber attack occurred on Evotec‘s IT systems. As a result, t |
|
| April 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2023 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 (Address of principal executive o |
|
| April 5, 2023 |
Exhibit 99.1 Notification of Major Holdings Page 1 | 5 Hamburg 22419 Essener Bogen 7 529900F9KI6OYITO9B12 Evotec SE X Notification of Major Holdings or Correction of a notification of Major Holdings dated 1. Details of issuer (name, address) Name Legal Entity Identifier (LEI) Street, Street number Postal code City 2. Reason for notification (multiple reasons possible) X Acquisition/disposal of sha |
|
| March 28, 2023 |
Evotec and Bristol Myers Squibb extend and expand strategic neurodegeneration partnership EXHIBIT 99.2 |
|
| March 28, 2023 |
EXHIBIT 99.1 |
|
| March 28, 2023 |
Evotec SE: Ahead of the curve – Leadership in our focus areas for medicines that matter EXHIBIT 99.2 |
|
| March 28, 2023 |
EXHIBIT 99.1 28 March 2023 Ad hoc release according to Article 17 MAR of the Regulation (EU) No 596/2014 Evotec and Bristol Myers Squibb expand strategic neurodegeneration partnership Hamburg, Germany – Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE 000 566480 9, WKN 566480; NASDAQ: EVO) announces today that the Company has extended and expanded its strategic partnership with Bris |
|
| March 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF MARCH 2023 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 (Address of principal executive of |
|
| March 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF MARCH 2023 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 (Address of principal executive of |
|
| February 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF FEBRUARY 2023 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 (Address of principal executive |
|
| February 7, 2023 |
EXHIBIT 99.1 Evotec SE: Laetitia Rouxel to succeed Enno Spillner as Chief Financial Officer 07.02.2023 / 07:30 CET/CEST The issuer is solely responsible for the content of this announcement. Hamburg, Germany, 07 February 2023: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced today that the Company's Supervisory Board has appointed Laetitia Rouxel as |
|
| February 2, 2023 |
EVTCY / Evotec AG / Novo Holdings A/S - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.1)* Evotec SE (Name of Issuer) Ordinary Shares, no par value per share (Title of Class of Securities) 30050E105 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule p |
|
| November 16, 2022 |
6-K 1 tm2230613d16k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2022 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 5608 |
|
| November 16, 2022 |
Exhibit 99.1 Notification of Major Holdings | Page 1 4 Hamburg 22419 Essener Bogen 7 529900F9KI6OYITO9B12 Evotec SE X Notification of Major Holdings or Correction of a notification of Major Holdings dated 1. Details of issuer (name, address) Name Legal Entity Identifier (LEI) Street, Street number Postal code City 2. Reason for notification (multiple reasons possible) X Acquisition/disposal of sha |
|
| November 9, 2022 |
Exhibit 99.1 For further information, please contact: Volker Braun, SVP Head of Global Investor Relations & ESG, [email protected], T. +49.(0)40.560 81-775, M. +49.(0)151.1940 5058, www.evotec.com interim STATEMENT 9M 2022 HIGHLIGHTS 4 multiple new and extended alliances in all areas 4 Paradigm shift in biologics Starting its market entry Strategy 4 commercial launch of next-generation multi |
|
| November 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2022 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 (Address of principal executiv |
|
| October 6, 2022 |
EX-99.1 2 tm2227728d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Stimmrechtsmitteilung | Seite 1 3 Hamburg 22419 Manfred Eigen Campus / Essener Bogen 7 529900F9KI6OYITO9B12 Evotec SE X Stimmrechtsmitteilung oder Korrektur einer Stimmrechtsmitteilung vom 1. Angaben zum Emittenten Name Legal Entity Identifier (LEI) Straße, Hausnr. PLZ Ort 2. Grund der Mitteilung (mehrere Angaben möglich) X Erwerb bzw. Verä |
|
| October 6, 2022 |
6-K 1 tm2227728d16k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2022 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 56081 |
|
| August 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2022 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant?s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 (Address of principal executive |
|
| August 11, 2022 |
Exhibit 99.1 For further information, please contact: Volker Braun, SVP Head of Global Investor Relations & ESG, [email protected], T. +49.(0)40.560 81-775, M. +49.(0)151.1940 5058, www.evotec.com HALF-YEAR REPORT 2022 I. MANAGEMENT REPORT 4 NEW AND EXTENDED ALLIANCES underline success of GROWTH STRATEGY 4 Acquisition expands capabilities and Expertise in cell therapy 4 Guidance for full-yea |
|
| June 24, 2022 |
6-K 1 tm2219410d16k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2022 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 ( |
|
| June 24, 2022 |
EX-99.1 2 tm2219410d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Notification of Major Holdings | Page 1 4 Hamburg 22419 Essener Bogen 7 529900F9KI6OYITO9B12 Evotec SE X Notification of Major Holdings or Correction of a notification of Major Holdings dated 1. Details of issuer (name, address) Name Legal Entity Identifier (LEI) Street, Street number Postal code City 2. Reason for notification (multiple re |
|
| June 23, 2022 |
Evotec SE reports results of Annual General Meeting 2022 EXHIBIT 99.1 Evotec SE reports results of Annual General Meeting 2022 · ALL AGENDA ITEMS ADOPTED WITH THE REQUIRED MAJORITY · CAMILLA MACAPILI LANGUILLE ELECTED AS NEW MEMBER OF THE SUPERVISORY BOARD; KASIM KUTAY RESIGNS FROM SUPERVISORY BOARD · AUTHORISED CAPITAL 2022 RESOLVED · REVISED REMUNERATION SYSTEM FOR MANAGEMENT BOARD APPROVED Hamburg, Germany, 22 June 2022: Evotec SE (Frankfurt Stock Ex |
|
| June 23, 2022 |
6-K 1 evo6k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF JUNE 2022 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 (Address o |
|
| June 23, 2022 |
Annual General Meeting 2022 Voting Results EXHIBIT 99.2 |
|
| June 9, 2022 |
6-K 1 tm2218076d16k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2022 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 ( |
|
| June 9, 2022 |
EX-99.1 2 tm2218076d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Notification of Major Holdings | Page 1 11 Hamburg 22419 Essener Bogen 7 529900F9KI6OYITO9B12 Evotec SE X Notification of Major Holdings or Correction of a notification of Major Holdings dated 1. Details of issuer (name, address) Name Legal Entity Identifier (LEI) Street, Street number Postal code City 2. Reason for notification (multiple r |
|
| June 7, 2022 |
6-K 1 tm2217889d16k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2022 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 ( |
|
| June 7, 2022 |
EX-99.1 2 tm2217889d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Notification of Major Holdings | Page 1 11 Hamburg 22419 Essener Bogen 7 529900F9KI6OYITO9B12 Evotec SE X Notification of Major Holdings or Correction of a notification of Major Holdings dated 1. Details of issuer (name, address) Name Legal Entity Identifier (LEI) Street, Street number Postal code City 2. Reason for notification (multiple r |
|
| June 3, 2022 |
6-K 1 tm2217690d16k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2022 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 ( |
|
| June 3, 2022 |
EX-99.1 2 tm2217690d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Notification of Major Holdings | Page 1 3 Hamburg 22419 Manfred Eigen Campus / Essener Bogen 7 529900F9KI6OYITO9B12 Evotec SE X Notification of Major Holdings or Correction of a notification of Major Holdings dated 1. Details of issuer (name, address) Name Legal Entity Identifier (LEI) Street, Street number Postal code City 2. Reason for no |
|
| May 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2022 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant?s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 (Address of principal executive off |
|
| May 11, 2022 |
Exhibit 99.1 For further information, please contact: Volker Braun, SVP Global Head of Investor Relations & ESG, [email protected], T. +49.(0)40.560 81-775, M. +49.(0)151.1940 5058, www.evotec.com INTERIM STATEMENT Q1 2022 HIGHLIGHTS 4 Strong performance leads to SIGNIFICANT revenue growth 4 Strong momentum in all BUSINESS areas 4 New partnerships BASED on Data-driven precision medicine PLAT |
|
| May 10, 2022 |
Evotec and Bristol Myers Squibb extend and expand strategic partnership in protein degradation EX-99.2 3 evoex992.htm EVOTEC AND BRISTOL MYERS SQUIBB EXTEND AND EXPAND STRATEGIC PARTNERSHIP IN PROTEIN DEGRADATION EXHIBIT 99.2 |
|
| May 10, 2022 |
Evotec and Bristol Myers Squibb extend and expand strategic partnership EX-99.1 2 evoex991.htm EVOTEC AND BRISTOL MYERS SQUIBB EXTEND AND EXPAND STRATEGIC PARTNERSHIP EXHIBIT 99.1 Evotec and Bristol Myers Squibb extend and expand strategic partnership Hamburg, Germany – Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE 000 566480 9, WKN 566480; NASDAQ: EVO) announces today that the Company has extended and expanded its partnership with Bristol Myers Squi |
|
| May 10, 2022 |
6-K 1 evo6k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF MAY 2022 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 (Address of |
|
| April 26, 2022 |
Consent of Independent Registered Public Accounting Firm BDO. Exhibit 15.1 Consent of Independent Registered Public Accounting Firm We hereby consent to the incorporation by reference in the Registration Statement on Form S8 (No. 333-260920) of Evotec SE of our report dated April 25, 2022, relating to the consolidated financial statements which appears in this Form 20-F. /s/ BDO AG Wirtschaftsprüfungsgesellschaft Frankfurt am Main, Germany April 26, 2022 |
|
| April 26, 2022 |
EX-16.1 13 evo-20211231xex16d1.htm EXHIBIT 16.1 Exhibit 16.1 April 26, 2022 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Ladies and Gentlemen: We have read the statements made by Evotec SE pursuant to the third paragraph of Item 16F of Form 20-F (copy attached), which we understand will be filed with the Securities and Exchange Commission on April 26, 2021. We agree w |
|
| April 26, 2022 |
Exhibit 13.2 Certification by the Principal Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of Evotec SE (the “Company”) on Form 20-F for the fiscal year ended December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Enno Spillner, Chief Financial Officer of the Company, certify, pu |
|
| April 26, 2022 |
Consent of Independent Registered Public Accounting Firm EY Exhibit 15.2 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the Registration Statement (Form S-8 No. 333-260920) pertaining to the Employees? Restricted Share Plan 2020 and Share Performance Plan 2017 of Evotec SE of our report dated July 9, 2021 (except for Note 4, to which the date is August 19, 2021), with respect to the consolidated fin |
|
| April 26, 2022 |
Company’s Specimen Certificate for Ordinary Shares. EX-2.4 4 evo-20211231xex2d4.htm EXHIBIT 2.4 Exhibit 2.4 WKN: 566480 ISIN: DE0005664809 Reference number: [●] [●] no-par stock Evotec SE Hamburg Global certificate for [•] bearer common stocks in the form of no-par stock Stock numbers: [●] to [●] The bearer of this global certificate is a shareholder of Evotec SE, Hamburg, in accordance with its Articles of Association and holds [●] no-par stocks. |
|
| April 26, 2022 |
Exhibit 12.2 CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER PURSUANT TO EXCHANGE ACT RULE 13A-14(A) OR 15D-14(A) AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Enno Spillner, certify that: 1. I have reviewed this annual report on Form 20-F of Evotec SE; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a mater |
|
| April 26, 2022 |
Exhibit 2.3 DESCRIPTION OF SECURITIES The following description sets forth certain material terms and provisions of ordinary shares and American Depositary Shares representing ordinary shares of Evotec SE (“us,” “our,” “we” or the “Company”) that are registered under Section 12 of the U.S. Securities Exchange Act of 1934, as amended. This description also summarizes certain provisions of our artic |
|
| April 26, 2022 |
Exhibit 12.1 CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO EXCHANGE ACT RULE 13A-14(A) OR 15D-14(A) AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Dr. Werner Lanthaler, certify that: 1. I have reviewed this annual report on Form 20-F of Evotec SE; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state |
|
| April 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 20-F Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF |
|
| April 26, 2022 |
Exhibit 13.1 Certification by the Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of Evotec SE (the “Company”) on Form 20-F for the fiscal year ended December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Dr. Werner Lanthaler, Chief Executive Officer of the Company, cert |
|
| April 26, 2022 |
Articles of Association of Evotec SE. Non-binding convenience translation ? Exhibit 1.1 ? A r t i c l e s o f A s s o c i a t i o n ? of Evotec SE ? ? ? I. General Provisions ? ? 1 Company and Registered Office ? (1)The name of the Company shall be: ? Evotec SE. ? (2)The registered office of the Company shall be in Hamburg. ? ? 2 Object of the Company ? (1) The object of the Company shall be research activities in the field of biologi |
|
| April 26, 2022 |
Stock Option Plan and Share Performance Plan 2017 for Management. EX-4.5 5 evo-20211231xex4d5.htm EXHIBIT 4.5 Exhibit 4.5 Share Performance Plan 2017 Terms and Conditions for EVOTEC’s Management Board Grant Date: 28 January 2022 Evotec SE Manfred Eigen Campus Essener Bogen 7 22419 Hamburg, Germany List of Content Objectives § 1 Eligibility 3 § 2 Annual Grant 3 § 3 Vesting Period 4 § 4 Performance Measurement Period 4 § 5 Key Performance Indicators 4 § 6 Exercise |
|
| April 12, 2022 |
Guidance 20221) at constant fx EXHIBIT 99.1 Evotec SE fiscal year 2021 results: 'Setting the Pace' on the data-driven R&D Autobahn to Cures · STRONG FINANCIAL RESULTS: 23% INCREASE IN GROUP REVENUES SIGNIFICANTLY EXCEEDING GUIDANCE · DATA-DRIVEN PLATFORMS AND TECHNOLOGIES INCREASE PROBABILITIES OF SUCCESS IN ALL MODALITIES · SUBSTANTIALLY STRENGTHENED BALANCE SHEET PROVIDING VERY GOOD FOUNDATION AND LEVERAGE FOR SUSTAINABLE, LO |
|
| April 12, 2022 |
6-K 1 evo6k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF APRIL 2022 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 (Address |
|
| April 12, 2022 |
EX-99.2 3 evoex992.htm EX 99.2 EXHIBIT 99.2 |
|
| February 4, 2022 |
6-K 1 evo6k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF FEBRUARY 2022 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 (Addre |
|
| February 4, 2022 |
EX-99.1 2 evoex991.htm EX-99.1 EXHIBIT 99.1 Evotec SE: Bayer discontinues clinical development candidate eliapixant (BAY1817080), Evotec regains the rights to all P2X3 assets Hamburg, Germany - Evotec SE (Frankfurt Stock Exchange, MDAX/TecDAX, ISIN: DE 000 566480 9, WKN 566480; NASDAQ) announces today that the Company has been informed by Bayer about a decision to discontinue the development of th |
|
| February 2, 2022 |
EVTCY / Evotec AG / Novo Holdings A/S - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Evotec SE (Name of Issuer) Ordinary Shares (Title of Class of Securities) 30050E105 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sche |
|
| November 16, 2021 |
EX-99.1 2 ss616499ex9901.htm JOINT FILING AGREEMENT Exhibit 99.1 JOINT FILING AGREEMENT This will confirm the agreement by and among all the undersigned that the Schedule 13D filed on or about this date and any amendments thereto with respect to the beneficial ownership by the undersigned of ordinary shares, no par value, of Evotec SE is being filed on behalf of each of the undersigned in accordan |
|
| November 16, 2021 |
EVTCY / Evotec AG / Mubadala Investment Co PJSC - SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Evotec SE (Name of Issuer) Ordinary Shares, no par value (Title of Class of Securities) 30050E105(1) (CUSIP Number) Mubadala Investment Company PJSC Attention: Treasury and Investor Relations P.O. Box 45005 Abu Dhabi United Arab Emirates +971 2 413 0000 ( |
|
| November 12, 2021 |
6-K 1 tm2131300d16k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2021 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 5608 |
|
| November 12, 2021 |
[email protected], T. +49.(0)40.560 81-775, M. +49.(0)151.1940 5058, www.evotec.com EX-99.1 2 tm2131300d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 For further information, please contact: Volker Braun, SVP Global Head of Investor Relations & ESG, [email protected], T. +49.(0)40.560 81-775, M. +49.(0)151.1940 5058, www.evotec.com INTERIM STATEMENT 9M 2021 HIGHLIGHTS 4 Strong operational performance leads to SIGNIFICANT revenue growth 4 Co-owned pipeline gaining momentum 4 j.pod® |
|
| November 9, 2021 |
Stock Option Plan and Share Performance Plan 2017 for Senior Executives. Exhibit 10.3 Share Performance Plan 2017 Terms and Conditions for EVOTEC’s Senior Executives Evotec AG Manfred Eigen Campus Essener Bogen 7 22419 Hamburg, Germany List of Content Objectives § 1 Eligibility 3 § 2 Annual Grant 3 § 3 Vesting Period 4 § 4 Performance Measurement Period 4 § 5 Key Performance Indicators 4 § 6 Exercise of Shares 5 § 7 Termination of employment contract 7 § 8 Change of Co |
|
| November 9, 2021 |
Stock Option Plan and Share Performance Plan 2017 for Management. EX-10.4 7 d233559dex104.htm EX-10.4 Exhibit 10.4 Restricted Share Plan 2020 Terms and Conditions for EVOTEC’s Management Board Evotec SE Manfred Eigen Campus Essener Bogen 7 22419 Hamburg, Germany List of Content Objectives § 1 Eligibility 3 § 2 Biannual Grant of Awards 3 § 3 Waiting Period and Exercise Period 4 § 4 Performance Period 4 § 5 Key Performance Indicator 4 § 6 Exercisable Restricted Sh |
|
| November 9, 2021 |
Restricted Share Plan 2020 for Non-Management. EX-10.2 5 d233559dex102.htm EX-10.2 Exhibit 10.2 Restricted Share Plan 2020 Terms and Conditions Evotec SE Manfred Eigen Campus Essener Bogen 7 22419 Hamburg, Germany List of Content Objectives § 1 Eligibility 3 § 2 Biannual Grant of Awards 3 § 3 Waiting Period and Exercise Period 4 § 4 Performance Period 4 § 5 Key Performance Indicator 4 § 6 Exercisable Restricted Share Awards 4 § 7 Exercise of S |
|
| November 9, 2021 |
As filed with the Securities and Exchange Commission on November 9, 2021 S-8 1 d233559ds8.htm S-8 As filed with the Securities and Exchange Commission on November 9, 2021 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Evotec SE (Exact name of registrant as specified in its charter) Federal Republic of Germany Not Applicable (State of incorporation or organizati |
|
| November 9, 2021 |
Restricted Share Plan 2020 for Management. EX-10.1 4 d233559dex101.htm EX-10.1 Exhibit 10.1 Restricted Share Plan 2020 Terms and Conditions for EVOTEC’s Management Board Evotec SE Manfred Eigen Campus Essener Bogen 7 22419 Hamburg, Germany List of Content Objectives § 1 Eligibility 3 § 2 Biannual Grant of Awards 3 § 3 Waiting Period and Exercise Period 4 § 4 Performance Period 4 § 5 Key Performance Indicator 4 § 6 Exercisable Restricted Sh |
|
| November 9, 2021 |
Articles of Association of Evotec SE. Exhibit 3.1 A r t i c l e s o f A s s o c i a t i o n of Evotec SE I. General Provisions § 1 Company and Registered Office (1) The name of the Company shall be: Evotec SE. (2) The registered office of the Company shall be in Hamburg. § 2 Object of the Company (1) The object of the Company shall be research activities in the field of biologically functional synthetic, semi-synthetic, and natural ac |
|
| November 5, 2021 |
20,000,000 American Depositary Shares Representing 10,000,000 Ordinary Shares Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No. 333-260143 PROSPECTUS 20,000,000 American Depositary Shares Representing 10,000,000 Ordinary Shares This is the initial public offering of American Depositary Shares, or ADSs, representing 10,000,000 ordinary shares of Evotec SE. We are offering 20,000,000 ADSs at an initial public offering price of $21.75 per ADS. The closing pri |
|
| November 1, 2021 |
BOFA SECURITIES, INC. One Bryant Park New York, New York 10036 CORRESP 1 filename1.htm BOFA SECURITIES, INC. One Bryant Park New York, New York 10036 MORGAN STANLEY & CO. LLC 1585 Broadway New York, New York 10036 Via EDGAR AND E-MAIL United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549-6010 November 1, 2021 Attention: Tracey Houser Brian Cascio Dillon Hagius Suzanne |
|
| November 1, 2021 |
EVOTEC SE Essener Bogen 7 22419 Hamburg November 1, 2021 CORRESP 1 filename1.htm EVOTEC SE Essener Bogen 7 22419 Hamburg Germany November 1, 2021 U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Tracey Houser, Brian Cascio, Dillon Hagius, Suzanne Hayes Re: Evotec SE Registration Statement on Form F-1 File No. 333-260143 Dear Ms. Houser, Mr. Cascio, Mr. Ha |
|
| November 1, 2021 |
8-A12B 1 d236556d8a12b.htm 8-A12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Evotec SE (Exact name of registrant as specified in its charter) Federal Republic of Germany Not Applicable (State of incorporation or organization) (I.R.S. Employ |
|
| October 29, 2021 |
As filed with the Securities and Exchange Commission on October 29, 2021. F-1/A 1 d166695df1a.htm F-1/A Table of Contents As filed with the Securities and Exchange Commission on October 29, 2021. Registration No. 333-260143 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 4 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Evotec SE (Exact Name of Registrant as Specified in Its Charter) Not Applicable (Translation o |
|
| October 29, 2021 |
CORRESP 1 filename1.htm Sophia Hudson, P.C. To Call Writer Directly: +1 212 446 4750 [email protected] 601 Lexington Avenue New York, NY 10022 United States +1 212 446 4800 www.kirkland.com Facsimile: +1 212 446 4900 October 29, 2021 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, D.C. 20549 Attention: Trace |
|
| October 28, 2021 |
CORRESP 1 filename1.htm Sophia Hudson, P.C. To Call Writer Directly: +1 212 446 4750 [email protected] 601 Lexington Avenue New York, NY 10022 United States +1 212 446 4800 www.kirkland.com Facsimile: +1 212 446 4900 October 28, 2021 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, D.C. 20549 Attention: Trace |
|
| October 28, 2021 |
As filed with the Securities and Exchange Commission on October 28, 2021. Table of Contents As filed with the Securities and Exchange Commission on October 28, 2021. |
|
| October 26, 2021 |
Form of Underwriting Agreement. Exhibit 1.1 Evotec SE (a European stock corporation organized under the laws of the Federal Republic of Germany and the European Union) [ ? ] American Depositary Shares Each Representing One-Half of One Ordinary Share in Bearer Form (no par value per share) UNDERWRITING AGREEMENT Dated: [ ? ], 2021 Evotec SE (a European stock corporation organized under the laws of Federal Republic of Germany and |
|
| October 26, 2021 |
CORRESP 1 filename1.htm Sophia Hudson, P.C. To Call Writer Directly: +1 212 446 4750 [email protected] 601 Lexington Avenue New York, NY 10022 United States +1 212 446 4800 www.kirkland.com Facsimile: +1 212 446 4900 October 26, 2021 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, D.C. 20549 Attention: Trace |
|
| October 26, 2021 |
As filed with the Securities and Exchange Commission on October 26, 2021. Table of Contents As filed with the Securities and Exchange Commission on October 26, 2021. |
|
| October 22, 2021 |
Sophia Hudson, P.C. To Call Writer Directly: +1 212 446 4750 [email protected] 601 Lexington Avenue New York, NY 10022 United States +1 212 446 4800 www.kirkland.com Facsimile: +1 212 446 4900 October 22, 2021 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, D.C. 20549 Attention: Tracey Houser, Brian Cascio, |
|
| October 22, 2021 |
Exhibit 16.1 October 22, 2021 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Ladies and Gentlemen: We have read the statements made by Evotec SE pursuant to Item 16F of Form 20-F (copy attached), which we understand will be filed with the Securities and Exchange Commission as part of Amendment No. 1 to the Registration Statement on Form F-1 of Evotec SE dated October 22 |
|
| October 22, 2021 |
Exhibit 4.3 TABLE OF CONTENTS Page PARTIES 1 RECITALS 1 Section 1. Certain Definitions (a) ADR Register 1 (b) ADRs; Direct Registration ADRs 1 (c) ADS 1 (d) Beneficial Owner 2 (e) CSB 2 (f) Custodian 2 (g) Deliver, execute, issue et al. 2 (h) Delivery Order 2 (i) Deposited Securities 2 (j) Direct Registration System 3 (k) Holder 3 (l) Securities Act of 1933 3 (m) Securities Exchange Act of 1934 3 |
|
| October 22, 2021 |
As filed with the Securities and Exchange Commission on October 22, 2021. F-1/A 1 d166695df1a.htm F-1/A Table of Contents As filed with the Securities and Exchange Commission on October 22, 2021. Registration No. 333-260143 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Evotec SE (Exact Name of Registrant as Specified in Its Charter) Not Applicable (Translation o |
|
| October 8, 2021 |
Articles of Association of the Registrant. Exhibit 3.1 A r t i c l e s o f A s s o c i a t i o n of Evotec SE I. General Provisions § 1 Company and Registered Office (1) The name of the Company shall be: Evotec SE. (2) The registered office of the Company shall be in Hamburg. § 2 Object of the Company (1) The object of the Company shall be research activities in the field of biologically functional synthetic, semi-synthetic, and natural ac |
|
| October 8, 2021 |
Investment Agreement between the Company and Novo Holdings A/S, dated October 12, 2020. Exhibit 4.5 THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED INVESTMENT AGREEMENT AMONG EVOTEC SE AND NOVO HOLDINGS A/S 12 OCTOBER 2020 CONTENTS Clause Page 1. ISSUE AND SUBSCRIPTION OF NEW SHARES 2 2. DELIVERY AND PAYMENT 3 |
|
| October 8, 2021 |
Exhibit 10.2 THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED DATED 28 SEPTEMBER 2007 MEPC MILTON PARK NO. 1 LIMITED and MEPC MILTON PARK NO. 2 LIMITED and EVOTEC (UK) LIMITED LEASE of Unit 117 Milton Park GllJlilB BrookStre |
|
| October 8, 2021 |
EX-10.11 18 d166695dex1011.htm EX-10.11 Exhibit 10.11 THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED Aptuit Agreement Reference: 00040069 Drug Discovery & Development Services Agreement Aptuit (Verona) Srl and Novo Nordisk |
|
| October 8, 2021 |
Exhibit 10.9 Promissory Notes (Schuldscheindarlehen) The seven promissory note loan agreements (collectively, the “Promissory Notes”) each govern an unsecured promissory note loan among Evotec SE, as borrower (the “Borrower”), Deutsche Bank AG and Landesbank Baden-Württemberg (“LBBW,” and, together with the Borrower and Deutsche Bank AG, the “Parties”), as arrangers and LBBW as the original lender |
|
| October 8, 2021 |
Stock Option Plan and Share Performance Plan 2017 for Management. Exhibit 10.5 Restricted Share Plan 2020 Terms and Conditions for EVOTEC?s Management Board Evotec SE Manfred Eigen Campus Essener Bogen 7 22419 Hamburg, Germany List of Content Objectives ? 1 Eligibility 3 ? 2 Biannual Grant of Awards 3 ? 3 Waiting Period and Exercise Period 4 ? 4 Performance Period 4 ? 5 Key Performance Indicator 4 ? 6 Exercisable Restricted Share Awards 4 ? 7 Exercise of Shares |
|
| October 8, 2021 |
Exhibit 10.10 C L I F F O R D C H A N C E CLIFFORD CHANCE LLP THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED EXECUTION VERSION AGREEMENT DATED 19 DECEMBER 2017 FOR EUROPEAN INVESTMENT BANK and EVOTEC AG RELATING TO A FINAN |
|
| October 8, 2021 |
Restricted Share Plan 2020 for Non-Management. Exhibit 10.7 Restricted Share Plan 2020 Terms and Conditions Evotec SE Manfred Eigen Campus Essener Bogen 7 22419 Hamburg, Germany List of Content Objectives § 1 Eligibility 3 § 2 Biannual Grant of Awards 3 § 3 Waiting Period and Exercise Period 4 § 4 Performance Period 4 § 5 Key Performance Indicator 4 § 6 Exercisable Restricted Share Awards 4 § 7 Exercise of Shares 5 § 8 Change of Control and Di |
|
| October 8, 2021 |
Powers of Attorney (included on signature page). Table of Contents As filed with the Securities and Exchange Commission on October 8, 2021. |
|
| October 8, 2021 |
Exhibit 4.3 TABLE OF CONTENTS Page PARTIES 1 RECITALS 1 Section 1. Certain Definitions (a) ADR Register 1 (b) ADRs; Direct Registration ADRs 1 (c) ADS 1 (d) Beneficial Owner 2 (e) CSB 2 (f) Custodian 2 (g) Deliver, execute, issue et al. 2 (h) Delivery Order 2 (i) Deposited Securities 2 (j) Direct Registration System 3 (k) Holder 3 (l) Securities Act of 1933 3 (m) Securities Exchange Act of 1934 3 |
|
| October 8, 2021 |
Exhibit 10.12 Evotec Version 1, 1st August 2019 THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED Drug Discovery & Development Services Agreement Evotec International GmbH and Novo Nordisk A/S This agreement (“Drug Discovery |
|
| October 8, 2021 |
Exhibit 10.3 THE SYMBOL ?[***]? DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED REDMOND RIDGE CORPORATE CENTER LEASE BY AND BElWEEN M&T PARTNERS, INC., a Delaware corporation AND JUST BIOTHERAPEUTICS, INC., a Delaware corporation, a member of |
|
| October 8, 2021 |
Exhibit 10.8 THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED SHARE PURCHASE AGREEMENT BY AND AMONG SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT AND EVOTEC (FRANCE) SAS Dated: July 1st, 2020 TABLE OF CONTENTS Article 1. Purchase |
|
| October 8, 2021 |
Exhibit 10.1 Lease Agreement – Essener Bogen 7 Since January 1 2011, Evotec AG (the “Company”) has rented office and laboratory space located at Essener Bogen 7 in Hamburg, Germany. The current monthly gross rent amounts to EUR 164,266.34, including ancillary costs of EUR 7,000. The landlord for the property is EuroCore Magnet S.à r.l (the “Landlord”). To date, the lease has been amended eight tim |
|
| October 8, 2021 |
CORRESP 1 filename1.htm 601 Lexington Avenue New York, NY 10022 Sophia Hudson, P.C. United States To Call Writer Directly: Facsimile: +1 212 446 4750 +1 212 446 4800 +1 212 446 4900 [email protected] www.kirkland.com October 8, 2021 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, D.C. 20549 Attention: Tracey |
|
| October 8, 2021 |
Table of Contents Exhibit 4.4 THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED INVESTMENT AGREEMENT AMONG EVOTEC SE AND ATIC SECOND INTERNATIONAL INVESTMENT COMPANY LLC 12 OCTOBER 2020 Table of Contents CONTENTS Clause Page |
|
| October 8, 2021 |
EX-16.1 21 d166695dex161.htm EX-16.1 Exhibit 16.1 October 8, 2021 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Ladies and Gentlemen: We have read the statements made by Evotec SE pursuant to Item 16F of Form 20-F (copy attached), which we understand will be filed with the Securities and Exchange Commission as part of the Registration Statement on Form F-1 of Evotec SE |
|
| October 8, 2021 |
Exhibit 10.13 EXECUTION VERSION 8 July 2020 THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED RESEARCH COLLABORATION AND LICENSE AGREEMENT by and between Novo Nordisk A/S and Evotec International GmbH EXECUTION VERSION 8 July |
|
| October 8, 2021 |
Registrant’s Specimen Certificate for Ordinary Shares. Exhibit 4.2 WKN: 566480 ISIN: DE0005664809 Ordnungsnummer: 43 [●] Stückaktien Evotec SE Hamburg Globalurkunde über [●] auf den Inhaber lautende Stammaktien in Form von Stückaktien Stückenummern: 171.192.909 bis [●] Der Inhaber dieser Globalurkunde ist mit [●] Stückaktien an der Evotec SE, Hamburg, nach Maßgabe der Satzung der Gesellschaft als Aktionär beteiligt. Die Anzahl der in dieser Globalurku |
|
| October 8, 2021 |
Restricted Share Plan 2020 for Management. EX-10.6 13 d166695dex106.htm EX-10.6 Exhibit 10.6 Restricted Share Plan 2020 Terms and Conditions for EVOTEC’s Management Board Evotec SE Manfred Eigen Campus Essener Bogen 7 22419 Hamburg, Germany List of Content Objectives § 1 Eligibility 3 § 2 Biannual Grant of Awards 3 § 3 Waiting Period and Exercise Period 4 § 4 Performance Period 4 § 5 Key Performance Indicator 4 § 6 Exercisable Restricted S |
|
| October 8, 2021 |
Stock Option Plan and Share Performance Plan 2017 for Senior Executives. Exhibit 10.4 Share Performance Plan 2017 Terms and Conditions for EVOTEC’s Senior Executives Evotec AG Manfred Eigen Campus Essener Bogen 7 22419 Hamburg, Germany List of Content Objectives § 1 Eligibility 3 § 2 Annual Grant 3 § 3 Vesting Period 4 § 4 Performance Measurement Period 4 § 5 Key Performance Indicators 4 § 6 Exercise of Shares 5 § 7 Termination of employment contract 7 § 8 Change of Co |
|
| October 8, 2021 |
List of Subsidiaries of the Registrant. Exhibit 21.1 2020 Company’s voting rights % Subsidiaries Aptuit Global LLC, Princeton, USA 100.00 Aptuit (Verona) SRL, Verona, Italy 100.00 Aptuit (Oxford) Ltd., Abingdon, UK 100.00 Aptuit (Switzerland) AG in Liquidation, Basel, Switzerland 100.00 Aptuit (Potters Bar) Ltd, Abingdon, UK 100.00 Cyprotex Discovery Ltd., Manchester, UK 100.00 Cyprotex PLC, Manchester, UK 100.00 Cyprotex US, LLC., Wate |
|
| September 22, 2021 |
EX-10.4 9 filename9.htm Exhibit 10.4 Share Performance Plan 2017 Terms and Conditions for EVOTEC’s Senior Executives Evotec AG Manfred Eigen Campus Essener Bogen 7 22419 Hamburg, Germany List of Content Objectives § 1 Eligibility 3 § 2 Annual Grant 3 § 3 Vesting Period 4 § 4 Performance Measurement Period 4 § 5 Key Performance Indicators 4 § 6 Exercise of Shares 5 § 7 Termination of employment con |
|
| September 22, 2021 |
EX-10.7 11 filename11.htm Exhibit 10.7 Restricted Share Plan 2020 Terms and Conditions Evotec SE Manfred Eigen Campus Essener Bogen 7 22419 Hamburg, Germany List of Content Objectives § 1 Eligibility 3 § 2 Biannual Grant of Awards 3 § 3 Waiting Period and Exercise Period 4 § 4 Performance Period 4 § 5 Key Performance Indicator 4 § 6 Exercisable Restricted Share Awards 4 § 7 Exercise of Shares 5 § |
|
| September 22, 2021 |
Exhibit 10.8 THE SYMBOL ?[***]? DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED SHARE PURCHASE AGREEMENT BY AND AMONG SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT AND EVOTEC (FRANCE) SAS Dated: July 1st, 2020 TABLE OF CONTENTS Article 1. Purchase |
|
| September 22, 2021 |
EX-4.2 3 filename3.htm Exhibit 4.2 WKN: 566480 ISIN: DE0005664809 Ordnungsnummer: 43 [●] Stückaktien Evotec SE Hamburg Globalurkunde über [●] auf den Inhaber lautende Stammaktien in Form von Stückaktien Stückenummern: 171.192.909 bis [●] Der Inhaber dieser Globalurkunde ist mit [●] Stückaktien an der Evotec SE, Hamburg, nach Maßgabe der Satzung der Gesellschaft als Aktionär beteiligt. Die Anzahl d |
|
| September 22, 2021 |
EX-3.1 2 filename2.htm Exhibit 3.1 A r t i c l e s o f A s s o c i a t i o n of Evotec SE I. General Provisions § 1 Company and Registered Office (1) The name of the Company shall be: Evotec SE. (2) The registered office of the Company shall be in Hamburg. § 2 Object of the Company (1) The object of the Company shall be research activities in the field of biologically functional synthetic, semi-sy |
|
| September 22, 2021 |
Exhibit 10.13 EXECUTION VERSION 8 July 2020 THE SYMBOL ?[***]? DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED RESEARCH COLLABORATION AND LICENSE AGREEMENT by and between Novo Nordisk A/S and Evotec International GmbH EXECUTION VERSION 8 July |
|
| September 22, 2021 |
EX-4.5 5 filename5.htm Exhibit 4.5 THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED INVESTMENT AGREEMENT AMONG EVOTEC SE AND NOVO HOLDINGS A/S 12 OCTOBER 2020 CONTENTS Clause Page 1. ISSUE AND SUBSCRIPTION OF NEW SHARES 2 2. |
|
| September 22, 2021 |
EX-4.4 4 filename4.htm Table of Contents Exhibit 4.4 THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED INVESTMENT AGREEMENT AMONG EVOTEC SE AND ATIC SECOND INTERNATIONAL INVESTMENT COMPANY LLC 12 OCTOBER 2020 Table of Content |
|
| September 22, 2021 |
Exhibit 10.10 C L I F F O R D C H A N C E CLIFFORD CHANCE LLP THE SYMBOL ?[***]? DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED EXECUTION VERSION AGREEMENT DATED 19 DECEMBER 2017 FOR EUROPEAN INVESTMENT BANK and EVOTEC AG RELATING TO A FINAN |
|
| September 22, 2021 |
EX-21.1 18 filename18.htm Exhibit 21.1 2020 Company’s voting rights % Subsidiaries Aptuit Global LLC, Princeton, USA 100.00 Aptuit (Verona) SRL, Verona, Italy 100.00 Aptuit (Oxford) Ltd., Abingdon, UK 100.00 Aptuit (Switzerland) AG in Liquidation, Basel, Switzerland 100.00 Aptuit (Potters Bar) Ltd, Abingdon, UK 100.00 Cyprotex Discovery Ltd., Manchester, UK 100.00 Cyprotex PLC, Manchester, UK 100. |
|
| September 22, 2021 |
Promissory Notes (Schuldscheindarlehen) EX-10.9 13 filename13.htm Exhibit 10.9 Promissory Notes (Schuldscheindarlehen) The seven promissory note loan agreements (collectively, the “Promissory Notes”) each govern an unsecured promissory note loan among Evotec SE, as borrower (the “Borrower”), Deutsche Bank AG and Landesbank Baden-Württemberg (“LBBW,” and, together with the Borrower and Deutsche Bank AG, the “Parties”), as arrangers and L |
|
| September 22, 2021 |
EX-10.5 10 filename10.htm Exhibit 10.5 Restricted Share Plan 2020 Terms and Conditions for EVOTEC’s Management Board Evotec SE Manfred Eigen Campus Essener Bogen 7 22419 Hamburg, Germany List of Content Objectives § 1 Eligibility 3 § 2 Biannual Grant of Awards 3 § 3 Waiting Period and Exercise Period 4 § 4 Performance Period 4 § 5 Key Performance Indicator 4 § 6 Exercisable Restricted Share Awards |
|
| September 22, 2021 |
EX-10.2 7 filename7.htm Exhibit 10.2 THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED DATED 28 SEPTEMBER 2007 MEPC MILTON PARK NO. 1 LIMITED and MEPC MILTON PARK NO. 2 LIMITED and EVOTEC (UK) LIMITED LEASE of Unit 117 Milton |
|
| September 22, 2021 |
EX-10.12 16 filename16.htm Exhibit 10.12 Evotec Version 1, 1st August 2019 THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED Drug Discovery & Development Services Agreement Evotec International GmbH and Novo Nordisk A/S This |
|
| September 22, 2021 |
Drug Discovery & Development Services Agreement Aptuit (Verona) Srl Novo Nordisk A/S EX-10.11 15 filename15.htm Exhibit 10.11 THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED Aptuit Agreement Reference: 00040069 Drug Discovery & Development Services Agreement Aptuit (Verona) Srl and Novo Nordisk A/S This agr |
|
| September 22, 2021 |
Lease Agreement – Essener Bogen 7 EX-10.1 6 filename6.htm Exhibit 10.1 Lease Agreement – Essener Bogen 7 Since January 1 2011, Evotec AG (the “Company”) has rented office and laboratory space located at Essener Bogen 7 in Hamburg, Germany. The current monthly gross rent amounts to EUR 164,266.34, including ancillary costs of EUR 7,000. The landlord for the property is EuroCore Magnet S.à r.l (the “Landlord”). To date, the lease ha |
|
| September 22, 2021 |
Exhibit 10.3 THE SYMBOL ?[***]? DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED REDMOND RIDGE CORPORATE CENTER LEASE BY AND BElWEEN M&T PARTNERS, INC., a Delaware corporation AND JUST BIOTHERAPEUTICS, INC., a Delaware corporation, a member of |
|
| September 22, 2021 |
DRS/A 1 filename1.htm Table of Contents As submitted confidentially with the Securities and Exchange Commission on September 21, 2021 as Amendment No. 2 to the draft registration statement. This Amendment No. 2 to the draft registration statement has not been publicly filed with the Securities and Exchange Commission and all information herein remains strictly confidential. Registration No. 333- U |
|
| September 21, 2021 |
DRSLTR 1 filename1.htm 601 Lexington Avenue New York, NY 10022 Sophia Hudson, P.C. United States To Call Writer Directly: Facsimile: +1 212 446 4750 +1 212 446 4800 +1 212 446 4900 [email protected] www.kirkland.com September 21, 2021 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, D.C. 20549 Attention: Trac |
|
| August 20, 2021 |
EX-3.1 Exhibit 3.1 A r t i c l e s o f A s s o c i a t i o n of Evotec SE I. General Provisions § 1 Company and Registered Office (1) The name of the Company shall be: Evotec SE. (2) The registered office of the Company shall be in Hamburg. § 2 Object of the Company (1) The object of the Company shall be research activities in the field of biologically functional synthetic, semi-synthetic, and nat |
|
| August 20, 2021 |
DRS/A 1 filename1.htm Table of Contents As submitted confidentially with the Securities and Exchange Commission on August 19, 2021 as Amendment No. 1 to the draft registration statement. This Amendment No. 1 to the draft registration statement has not been publicly filed with the Securities and Exchange Commission and all information herein remains strictly confidential. Registration No. 333- UNIT |
|
| August 19, 2021 |
Sophia Hudson, P.C. To Call Writer Directly: +1 212 446 4750 DRSLTR 1 filename1.htm Sophia Hudson, P.C. To Call Writer Directly: +1 212 446 4750 [email protected] 601 Lexington Avenue New York, NY 10022 United States +1 212 446 4800 www.kirkland.com Facsimile: +1 212 446 4900 August 19, 2021 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, D.C. 20549 Attention: Tracey |
|
| July 9, 2021 |
DRS 1 filename1.htm Table of Contents As submitted confidentially with the Securities and Exchange Commission on July 9, 2021 This draft registration statement has not been publicly filed with the Securities and Exchange Commission and all information herein remains strictly confidential Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-1 REGISTRA |
|
| July 9, 2021 |
Articles of Association of Evotec SE General Provisions § 1 Company and Registered Office EX-3.1 2 filename2.htm Exhibit 3.1 Non-binding convenience translation Articles of Association of Evotec SE I. General Provisions § 1 Company and Registered Office (1) The name of the Company shall be: Evotec SE. (2) The registered office of the Company shall be in Hamburg. § 2 Object of the Company (1) The object of the Company shall be research activities in the field of biologically functional |
|
| December 30, 2010 |
AMENDMENT NO. 1 TO DEPOSIT AGREEMENT AMENDMENT NO. 1 TO DEPOSIT AGREEMENT AMENDMENT NO. 1 dated as of December 30, 2010 (the "Amendment") to the Deposit Agreement dated as of April 15, 2008 (as amended from time to time, the "Deposit Agreement") among Evotec Aktiengesellschaft incorporated under the laws of the Federal Republic of Germany, and its successors (the "Company"), JPMorgan Chase Bank, N.A., as depositary (the "Depositary") |
|
| December 30, 2010 |
Certification under Rule 466 The depositary, JPMorgan Chase Bank, N.A. represents and certifies the following: (1) That it previously had filed a registration statement on Form F-6 (Evotec Aktiengesellschaft, 333-148604) that the Commission declared effective, with terms of deposit identical to the terms of deposit of this registration statement. (2) That its ability to designate the date and time |
|
| December 30, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15F CERTIFICATION OF A FOREIGN PRIVATE ISSUER?S TERMINATION OF REGISTRATION OF A CLASS OF SECURITIES UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ITS TERMINATION OF THE DUTY TO FILE REPORTS UNDER SECTION 13(a) OR SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-34041 Evotec |
|
| December 30, 2010 |
As filed with the U.S. Securities and Exchange Commission on December 30, 2010 As filed with the U.S. Securities and Exchange Commission on December 30, 2010 Registration No. 333-148604 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST EFFECTIVE AMENDMENT NO. 1 TO FORM F-6 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 For Depositary Shares Evidenced by American Depositary Receipts Evotec Aktiengesellschaft (Exact name of issuer of deposited securities |
|
| December 30, 2010 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 December 30, 2010 Evotec Aktiengesellschaft (Exact name of registrant as specified in its charter) Commission File Number: 001-34041 Evotec AG Schnackenburgallee 114 22525 Hamburg Germany (49-40) |
|
| December 30, 2010 |
As filed with the Securities and Exchange Commission on December 30, 2010 As filed with the Securities and Exchange Commission on December 30, 2010 Registration No. |
|
| November 16, 2010 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the period ended September 30, 2010 Evotec Aktiengesellschaft (Exact name of registrant as specified in its charter) Commission File Number: 001-34041 Evotec AG Schnackenburgallee 114 22525 H |
